In an adult clinical trial, informed consent is a conversation between two parties: the participant and the study team. In a pediatric trial, it’s a conversation between at least three, the child, the parent or guardian, and the healthcare provider. Each of them may understand the study differently, want different things from it, or weigh its risks and benefits on different scales.
That complexity is one of the central design challenges, especially in rare epilepsies and developmental epileptic encephalopathies (DEEs), where the therapeutic stakes are high, populations are small, and every family’s decision to enroll matters enormously to a study’s success.
Why Is Pediatric Consent More Than “Adult Consent, Simplified”?
The instinct might be to treat pediatric consent as a scaled-down version of the adult process; same document, smaller words. But that undersells what’s happening.
Consent forms are often dense with legal and scientific terminology to begin with, which already puts real comprehension at risk for adult participants. For children and adolescents, that complexity can be genuinely disqualifying. If a participant, or their parent/guardian, doesn’t fully grasp what they’re agreeing to, the ethical foundation of the trial is compromised, regardless of how carefully the protocol was designed.
There’s also a more subtle risk on the caregiver side, therapeutic misconception. Parents/guardians of children with severe, treatment-resistant conditions are often highly motivated to find something that works. That motivation can make it harder to fully absorb that a clinical trial is research, not guaranteed treatment, and that risks are real and not yet fully characterized. Bridging that gap requires a deliberate communication strategy.
What Happens When the Child & the Parent/Guardian Don’t Agree?
Ethical guidelines are clear that children should be asked for their assent, an age-appropriate form of agreement, even though legal consent rests with a parent or guardian. In practice, this is one of the harder needles to thread in pediatric research.
Cognitive and developmental abilities vary enormously among children with epilepsy. Some children with focal or generalized epilepsy may have age-appropriate cognitive function and be able to meaningfully participate in discussions about study participation. Others, particularly those with DEEs such as Dravet syndrome, Lennox-Gastaut syndrome, Rett syndrome, or CDKL5 deficiency disorder, may experience cognitive, communication, or neurodevelopmental challenges that affect their ability to understand research concepts or express preferences. As a result, assent capacity must be assessed individually rather than assumed based on age or diagnosis. While some adolescents can meaningfully engage in decisions about study participation and express informed preferences, others can’t. And occasionally, a child’s wishes and a parent or guardian’s decision genuinely conflict — a scenario that places weight on the research team to carefully navigate.
There’s no universal script for this. What works is a flexible approach that scales the depth and format of information to the individual child, not the average one.
What Does Innovation Look Like Here?
A few approaches have emerged and can help improve understanding and support meaningful participation in the assent:
- Visual aids, including interactive videos, infographics, and storybooks, that translate procedural information (e.g., blood draws, physical exams, and questionnaires) into something a child can picture and understand, rather than just hear described.
- Involving child psychologists, pediatric specialists, and communication experts directly in the consent conversation, so information is delivered in a developmentally appropriate way and adapted to the child’s individual needs and abilities rather than a clinically efficient one.
- Designing for reassurance, not just disclosure, making it explicit and repeated that questions are welcome, discomfort can be expressed, a child can say no or change their mind later, and won’t be treated differently either way.
This last point is worth additional focus. A well-designed pediatric assent tool doesn’t just explain the study. Instead, it explicitly tells a child that “no” is a safe answer, that they can say “yes” and later change to “no,” and that their care won’t change based on their decision. That’s a fundamentally different communication goal than an adult consent form is built for, and it takes deliberate design to get right.
Why Isn’t Cultural Context Optional?
Comprehension isn’t the only barrier. In many communities, mistrust of the medical system, limited awareness of what a clinical trial involves, or concern about exposing a child to a novel treatment can all make enrollment a harder decision, independent of how clear the consent materials are. Underserved populations often face this most acutely, where access to both healthcare and research literacy is already limited.
Addressing this well means treating cultural and socioeconomic context as a design input from the start, not a barrier to work around after the fact.
Why Does This Matter Beyond the Ethics Committee?
Getting pediatric permission and assent right isn’t just a compliance box. It also shapes enrollment, retention, and how representative the study population is, which are often among the hardest things to achieve in rare and ultra-rare epilepsies. A family that doesn’t fully understand the process, or doesn’t trust it, may be more likely to decline, or to withdraw partway through.
In that sense, developmentally appropriate permission and assent are first and foremost ethical safeguards. When done well, they can also build trust, lead to better-informed enrollment decisions, and help prevent withdrawals caused by misunderstanding or unmet expectations.
Worldwide Clinical Trials has direct experience building visual, age-appropriate assent tools for pediatric epilepsy studies. Contact us to learn more.
